Why Teva Pharma (TEVA) Should Settle With Novartis - Leerink
Get Alerts TEVA Hot Sheet
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Leerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on Teva Pharma (NYSE: TEVA) and cut the price target to $61 from $66. After losing an IPR decision on two Copaxone 40mg anchor patents, the analyst believes TEVA’s share price implies a generic entrant sometime in 2H17. In order to mitigate EPS downside in 2017-18 and eliminate business uncertainty, he believes the most prudent course of action is for TEVA to settle with the most credible generic threat Novartis AG (NYSE: NVS) for market entry in 1Q’18.
The Copaxone 40mg brand has five very similar method-of-use patents covering its 40mg formulation to treat relapsingremitting multiple sclerosis (RRMS) with three subcutaneous (Copaxone 40mg) injections over seven days. On 8/24, the Patent Trial and Review Board’s (PTAB) invalidated two of the Copaxone patents subject to inter partes review (IPR) proceeding, US patent #8,232,250 & #8,399,413, on grounds those patents were obvious in view of prior art disclosures. A decision on US patent #8,969,302, which has very similar subject matter as '250/'413, is expected on or before 9/1.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $50.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners
- TD Cowen Resumes EQT Corp. (EQT) at Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!